Your browser doesn't support javascript.
loading
A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.
Kuo, J C; Graham, D M; Salvarrey, A; Kassam, F; Le, L W; Shepherd, F A; Burkes, R; Hollen, P J; Gralla, R J; Leighl, N B.
Afiliação
  • Kuo JC; Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.
  • Graham DM; University of New South Wales, Sydney, Australia.
  • Salvarrey A; Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.
  • Kassam F; Queen's University Belfast, Belfast, U.K.
  • Le LW; Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.
  • Shepherd FA; Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.
  • Burkes R; Division of Medical Oncology, Southlake Regional Cancer Centre, Newmarket, ON.
  • Hollen PJ; Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.
  • Gralla RJ; Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.
  • Leighl NB; Division of Medical Oncology, Mount Sinai Hospital, Toronto, ON.
Curr Oncol ; 27(2): e156-e162, 2020 04.
Article em En | MEDLINE | ID: mdl-32489264
Introduction: Improving health-related quality of life (hrqol) is a key goal of systemic therapy in advanced lung cancer, although routine assessment remains challenging. We analyzed the impact of a real-time electronic hrqol tool, the electronic Lung Cancer Symptom Scale (elcss-ql), on palliative care (pc) referral rates, patterns of chemotherapy treatment, and use of other supportive interventions in patients with advanced non-small-cell lung cancer (nsclc) receiving first-line chemotherapy. Methods: Patients with advanced nsclc starting first-line chemotherapy were randomized to their oncologist receiving or not receiving their elcss-ql data before each clinic visit. Patients completed the elcss-ql at baseline, before each chemotherapy cycle, and at subsequent follow-up visits until disease progression. Prospective data about the pc referral rate, hrqol, and use of other supportive interventions were collected. Results: For the 95 patients with advanced nsclc who participated, oncologists received real-time elcss-ql data for 44 (elcss-ql arm) and standard clinical assessment alone for 51 (standard arm). The primary endpoint, the pc referral rate, was numerically higher, but statistically similar, for patients in the elcss-ql and standard arms. The hrqol scores over time were not significantly different between the two study arms. Conclusions: The elcss-ql is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study. Improving access to supportive care through the collection of patient-reported outcomes and hrqol should be an important component of care for patients with advanced lung cancer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cuidados Paliativos / Qualidade de Vida / Carcinoma Pulmonar de Células não Pequenas / Eletrônica / Medidas de Resultados Relatados pelo Paciente / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cuidados Paliativos / Qualidade de Vida / Carcinoma Pulmonar de Células não Pequenas / Eletrônica / Medidas de Resultados Relatados pelo Paciente / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article